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ABSTRACT
Background  Aiming at therapeutic targets has reduced 
the risk of organ failure in many diseases such as 
diabetes or hypertension. Such targets have not been 
deﬁ  ned for rheumatoid arthritis (RA).
Objective  To develop recommendations for achieving 
optimal therapeutic outcomes in RA.
Methods  A task force of rheumatologists and a patient 
developed a set of recommendations on the basis of 
evidence derived from a systematic literature review 
and expert opinion; these were subsequently discussed, 
amended and voted upon by >60 experts from various 
regions of the world in a Delphi-like procedure. Levels 
of evidence, strength of recommendations and levels of 
agreement were derived.
Results  The treat-to-target activity resulted in 10 
recommendations. The treatment aim was deﬁ  ned as 
remission with low disease activity being an alternative 
goal in patients with long-standing disease. Regular 
follow-up (every 1–3 months during active disease) 
with appropriate therapeutic adaptation to reach the 
desired state within 3 to a maximum of 6 months was 
recommended. Follow-up examinations ought to employ 
composite measures of disease activity which include 
joint counts. Additional items provide further details for 
particular aspects of the disease. Levels of agreement 
were very high for many of these recommendations 
(≥9/10).
Conclusion  The 10 recommendations are supposed to 
inform patients, rheumatologists and other stakeholders 
about strategies to reach optimal outcomes of RA based 
on evidence and expert opinion.
INTRODUCTION
Over the past 15 years, rheumatologists have devel-
oped and witnessed many paradigmatic changes 
in the treatment of rheumatoid arthritis (RA). 
However, these insights have not yet been clearly 
formulated. Consequently, many of these changes 
have not been brought into effect in most countries 
in Europe and other parts of the world.
In many other areas of medicine, treatment tar-
gets have been deﬁ  ned to improve outcomes, lead-
ing to a reduction in the risk of organ damage.1–7 In 
the care of patients with diabetes, hyperlipidaemia 
and hypertension, these aspects have been adopted 
widely in practice; doctors order laboratory tests 
for cholesterol and triglycerides, blood glucose 
and HbA1c levels, check blood pressure and adapt 
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therapy accordingly, and patients know these val-
ues and are aware of the treatment targets.
In RA, joint damage and physical disability are 
the major adverse outcomes associated with reduc-
tion in quality of life and premature mortality.8–11 
In turn, disease activity—as reﬂ  ected by swollen 
joint counts, levels of acute phase reactants or by 
composite indices of disease activity—is a good 
predictor of damage and physical disability.12–20
The paradigmatic changes mentioned above are 
related to several factors. First, less joint damage 
and better physical function have been unequivo-
cally shown to be a consequence of the early insti-
tution of disease-modifying antirheumatic drugs 
(DMARDs) when compared with their delayed 
start.21 22 Second, the deﬁ  nition of core set vari-
ables and development of composite measures 
to assess RA has allowed disease activity to be 
assessed reliably.23–26 Third, newly licensed medi-
cations, especially biological agents, have enabled 
the attainment of unprecedented outcomes.23 27 
Fourth, structured patient management aiming 
for a treatment target, usually low disease activity 
(LDA), leads to better outcomes than traditional 
means of follow-up.28–30
Finally, today remission is an achievable goal 
in many patients in clinical trials and clinical 
practice,31–34 and rapid attainment of remission 
can halt joint damage irrespective of the type of 
DMARD, synthetic or biological.20 Nevertheless, 
patients enrolled in recent clinical trials have often 
received only a very small number of DMARDs 
despite long disease duration,35–37 indicating 
inadequate treatment, although rheumatologists 
appear to be well-informed of recent insights on 
treating RA.38
The objective of the task force was to formulate 
a consensus on a set of recommendations aimed at 
improving the management of RA in clinical prac-
tice, thus providing guidance for treatment to target 
(‘T2T’). The consensus ﬁ  nding was based on evi-
dence obtained from a systematic literature review 
which revealed improved outcomes with strategic 
therapeutic approaches.39
METHODS
This activity comprised several steps. First, a 
Steering Committee consisting of rheumatologists 
and a patient with RA (the authors), who were 
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identiﬁ  ed on the basis of their expertise in treating RA, partic-
ipation in clinical trials, development of consensus statements 
and regional distribution across Europe and North America, was 
assembled in 2008.
The Steering Committee regarded a comprehensive sys-
tematic literature review as a mandatory initial step to serve 
as a basis for consensus on the deﬁ  nition of treatment targets. 
After deﬁ  nition of search questions, the literature review was 
performed by a fellow (MS) and is published in detail as an 
accompanying paper.39 On this basis, the Steering Committee 
formulated a provisional set of recommendations in line with 
European League Against Rheumatism (EULAR) standardised 
operating procedures40 at a second meeting.
In March 2009 these provisional recommendations were 
presented for discussion, amendment and voting to more than 
60 experts from Europe, North and Latin America, Japan and 
Australia, including ﬁ   ve patient representatives. The level of 
evidence and strength of each recommendation were deter-
mined41 42 and categorised as A (highest) to D (lowest) on the 
basis of the systematic literature review39 as ratiﬁ   ed by the 
Steering Committee.
Discussions took place in breakout and plenary sessions at 
the expert summit and decisions were made using a modiﬁ  ed 
Delphi technique.43 Each statement was then voted upon in an 
anonymous fashion using a digital system. Statements supported 
by ≥75% of votes were accepted while those with ≤25% were 
rejected outright. Others were subjected to further discussion 
and subsequent voting where ≥67% support or, in an eventual 
third round, a majority of ≥50% was needed. Subsequently, the 
group voted on the level of agreement with each of the derived 
bullet points using a 10-point numerical rating scale (1=do not 
agree at all, 10=agree completely).
The statements were then sent by email for ﬁ  nal comments. 
Only suggestions for improvements of clarity of wording or 
removal of redundancies were considered. Proposed changes to 
the meaning were not accepted, although they will be mostly 
dealt with in the comments to each bullet point.
RESULTS
Evidence-based approach
The ﬁ  nal step of the systematic literature review included only 
19 full papers and 5 recent abstracts that had targeted therapy as 
a research focus. The results are published in detail in an accom-
panying paper.39
Statements
The statements receiving a majority vote by the Expert 
Committee in the ﬁ  nal voting round are shown in Box 1. These 
are discussed in detail below. 
Overarching principles
The Committee felt that certain aspects related to the treatment 
of RA form a framework on which speciﬁ  c recommendations 
can be based. These items were therefore considered to consti-
tute overarching principles, although they were discussed and 
voted on.
(A) The treatment of rheumatoid arthritis must be based on a 
shared decision between patient and rheumatologist. Not only 
must the patient be informed on the therapeutic options and the 
reasons for recommending a particular therapeutic approach by 
weighing beneﬁ  t and risk, but the patient should participate in 
the decision as to which treatment should be applied. This item 
was accepted unanimously.
(B) The primary goal of treating the patient with rheuma-
toid arthritis is to maximise long-term health-related quality 
of life through control of symptoms, prevention of structural 
damage, normalisation of function and social participation. 
This general statement pertains to all aspects of the therapeutic 
procedures including selection of drugs, application of treatment 
strategies and follow-up of RA (81.6% acceptance).
(C) Abrogation of inﬂ  ammation is the most important way 
to achieve these goals. This principle relates to the fact that 
the inﬂ   ammatory response underlying RA is responsible for 
the signs and symptoms of the disease and is associated with 
adverse outcomes in all areas listed in (B)12 13 19 44 45 (72.9% 
acceptance in the second voting round). There was discussion 
as to whether the term ‘abrogation’ could be easily translated 
into other languages; to this end, synonyms such as abolition, 
reversal, suppression, halt, arrest, stop or inhibition reﬂ  ect the 
meaning, although abrogation leaves less room for residual 
interpretations than most other terms.
(D) Treatment to target by measuring disease activity and 
adjusting therapy accordingly optimises outcomes in rheuma-
toid arthritis. While the endeavour was to focus on individual 
items related to the topic of T2T, the Expert Committee felt so 
convinced on the principal nature and truthfulness of this state-
ment that 91.8% of the experts accepted it.
Recommendations
The overarching principles are followed by the ﬁ  nal set of 10 
recommendations as formulated by the Expert Committee. The 
sequence follows a hierarchical and a logical order; for example, 
the ﬁ  rst statement was regarded as the most important one, 
but other items were also deemed important. The weight of 
the individual items is reﬂ  ected by the level of evidence, the 
strength of recommendation and level of agreement as pre-
sented in table 1.
(1) The primary target for treatment of rheumatoid arthritis 
should be a state of clinical remission. The level of evidence 
supporting this statement was low (category III or IV) because 
strategic trials have hitherto aimed at attaining LDA,28–30 while 
no formal study compared a strategy to treat RA with the target 
‘remission’ with another strategy. Some trials evaluated the fre-
quencies of remission by different therapies46 or had remission 
as the primary end point32 46 but, with one exception,46 this was 
investigated with static treatment and not by strategic switching. 
On the other hand, the functional and radiographic outcomes 
of these latter trials provide important supportive evidence for 
the statement. Also, subanalyses of various clinical trials sug-
gest that the best outcomes are achieved on attaining remission, 
even when compared with LDA.20 47 Moreover, remission can be 
achieved in a signiﬁ  cant proportion of patients, especially with 
early RA. It was therefore deemed to be a pivotal aspirational 
target for all patients (83% support; average agreement 9.1/10). 
The importance of sustained remission is addressed later.
(2) Clinical remission is deﬁ  ned as the absence of signs and 
symptoms of signiﬁ  cant inﬂ  ammatory disease activity. This 
statement is entirely expert-based (category IV). While there 
are many deﬁ  nitions of remission, such as that by the American 
College of Rheumatology (ACR) or based on composite disease 
activity measures14 48 49 and all of them are contained in the 
EULAR/ACR recommendations for clinical trial reporting,50 51 it 
is well established that some criteria allow for more residual dis-
ease activity than others.14 52 53 Furthermore, even when swell-
ing cannot be discerned clinically, it may continue to exist at a 
subclinical level.54 55 The majority of the experts felt that the def-
inition of remission should not allow for residual clinical disease 
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activity. On the other hand, it was accepted that some residual 
joint tenderness or a single swollen joint in a patient with long-
standing disease may still be compatible with a state of remis-
sion. The term remission of ‘inﬂ  ammatory disease activity’ was 
therefore coined, given that joint swelling and C-reactive pro-
tein (CRP) but not isolated tenderness or pain are associated 
with progression of joint damage.13 The term ‘signiﬁ  cant’ makes 
clear that a higher than very small level of residual inﬂ  ammatory 
activity was not acceptable, in line with survey results.56 In this 
regard, acute phase reactants such as CRP have also to be taken 
into account, as their increase likewise reﬂ  ects inﬂ  ammatory 
disease activity (see also statement 9). The ﬁ  nal voting achieved 
approval by 76% of the experts. An ACR/EULAR initiative on 
deﬁ  ning remission is currently ongoing.
(3) While remission should be a clear target, based on 
available evidence low disease activity may be an accept-
able alternative therapeutic goal, particularly in established 
long-standing disease. This statement conﬁ  rms remission as 
the ultimate therapeutic goal. Nevertheless, since all strategic 
clinical trials have focused on LDA,28–30 the target with the 
best evidence is a state of LDA according to established cut-off 
points of composite measures (category Ib). In patients with 
long-standing disease, considerable joint damage and several 
prior treatment failures, remission may not be realistic and LDA 
may be the best achievable state. Indeed, many patients with 
established RA may prefer to accept an ‘LDA state’ above forc-
ing them into remission at all costs. Importantly, however, LDA 
should be the minimal aspired goal (an ‘acceptable alternative to 
remission’), and patients clearly should not remain in moderate 
or high disease activity states. Finally, when LDA is an alterna-
tive target, it is important to sustain it (as was stated for remis-
sion; see also point 8).
(4) Until the desired treatment target is reached, drug ther-
apy should be adjusted at least every 3 months. Clinical trials 
suggest that the maximal clinical beneﬁ  t is usually not achieved 
before 3 months of treatment. A change of DMARD therapy has 
been done successfully every 1–3 months in strategic trials.28 30 
Thus, if patients do not attain at least a state of LDA within 
3 months from starting therapy, treatment should be amended 
(category Ib). This does not necessarily mean a change of drugs, 
since the degree of the change of disease activity from base-
line has to be taken into account in individual patients, espe-
cially in those with high disease activity at the start of therapy. 
Dose adaptation of existing medication may be sufﬁ  cient for 
further beneﬁ  t to be judged over the subsequent 1–3 months. 
On the other hand, in patients in whom the disease activity did 
not show major improvement within 3 months, changing the 
drug regimen may have to be considered at that early point in 
time. The choice of this time point is supported by respective 
studies.28–30 47 57
(5) Measures of disease activity must be obtained and docu-
mented regularly, as frequently as monthly for patients with 
high/moderate disease activity or less frequently (such as every 
Box 1  Recommendations
Overarching principles
(A) The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist.
(B) The primary goal of treating the patient with rheumatoid arthritis is to maximise long-term health-related quality of life through control 
of symptoms, prevention of structural damage, normalisation of function and social participation.
(C) Abrogation of inﬂ  ammation is the most important way to achieve these goals.
(D) Treatment to target by measuring disease activity and adjusting therapy accordingly optimises outcomes in rheumatoid arthritis.
10 recommendations on treating rheumatoid arthritis to target based on both evidence and expert opinion:
  (1)   The primary target for treatment of rheumatoid arthritis should be a state of clinical remission.
  (2)   Clinical remission is deﬁ  ned as the absence of signs and symptoms of signiﬁ  cant inﬂ  ammatory disease activity.
  (3)   While remission should be a clear target, based on available evidence low disease activity may be an acceptable alternative 
therapeutic goal, particularly in established long-standing disease.
  (4) Until the desired treatment target is reached, drug therapy should be adjusted at least every 3 months.
  (5)   Measures of disease activity must be obtained and documented regularly, as frequently as monthly for patients with high/moderate 
disease activity or less frequently (such as every 3–6 months) for patients in sustained low disease activity or remission.
  (6)   The use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical practice to 
guide treatment decisions.
  (7)   Structural changes and functional impairment should be considered when making clinical decisions, in addition to assessing 
composite measures of disease activity.
  (8) The desired treatment target should be maintained throughout the remaining course of the disease.
  (9)   The choice of the (composite) measure of disease activity and the level of the target value may be inﬂ  uenced by consideration of 
co-morbidities, patient factors and drug-related risks.
(10)   The patient has to be appropriately informed about the treatment target and the strategy planned to reach this target under the 
supervision of the rheumatologist.
Table 1 Evidence, agreement and votes for each of the 
recommendations
Item
Category of 
evidence
Strength of 
recommendation
Level of 
agreement
Percentage of votes at 
last ballot (number of 
ballots*)
1 III C 9.1 83 (1)
2 IV D 7.8 76 (8)
3 Ib A 8.6 77 (3)
4 Ib A 8.7 77 (6)
5 IV D 8.5 53 (3)
6 IV D 9.0 93.4 (5)
7 IV D 9.3 79.6 (9)
8 III C 9.7 92.6 (1)
9 IV D 9.5 74.5 (3)
10 IV D 9.3 90.6 (4)
*For several of the items the number of votes relates to the details of the wording, 
while the inclusion of the statement has been agreed upon at earlier ballots.
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experienced in reading these images. In addition to joint dam-
age, continuing impairment of physical function despite achieve-
ment of the targeted disease activity level may also necessitate 
a therapeutic change (category IV). However, in some patients, 
functional impairment may not be sufﬁ  ciently captured by func-
tional measures, particularly in individuals with certain occu-
pations who experience reduction in functioning and personal 
working capacity by involvement of a speciﬁ  c joint, necessitat-
ing a change of treatment even if otherwise in LDA. Thus, spe-
cial treatment options may be needed for optimal caretaking of 
individual patients.
(8) The desired treatment target should be maintained 
throughout the remaining course of the disease. Once disease 
activity has been titrated to the desired therapeutic target such 
as remission, this state should be maintained continuously (cat-
egory III). First, only sustained/persistent remission will lead to a 
halt in damage20 63; second, any increase in disease activity may 
reignite the destructive process.64 Caution is needed to govern 
decisions to reduce (dose or interval of) synthetic or biological 
DMARD treatment, let alone stopping it. Stopping synthetic 
DMARD therapy in remission was followed by twice as many 
ﬂ  are-ups and difﬁ  culties in reintroducing remission.65 Similar 
studies are not available for the biological agents.
(9) The choice of the (composite) measure of disease activity 
and the level of the target value may be inﬂ  uenced by consider-
ation of co-morbidities, patient factors and drug-related risks. 
Measures of disease activity, such as DAS, DAS28, SDAI, CDAI, 
comprise several variables and some of these may be affected 
by comorbidities or other patient factors and thus partly invali-
date the result obtained (category IV). For example, tender joints 
and patient’s assessment of disease activity may be exaggerated 
in certain concomitant diseases such as ﬁ  bromyalgia; or when 
erythrocyte sedimentation rate (ESR) is employed, diseases 
with abnormalities of the ESR may inﬂ  uence the score. It is then 
necessary to interpret the individual components of composite 
measures. Likewise, the target value may have to be eased in 
patients with certain comorbidities (or certain comedications); 
such comorbidities may be chronic infections, renal or hepatic 
functional impairment, congestive heart failure and others.
(10) The patient has to be appropriately informed about the 
treatment target and the strategy planned to reach this target 
under the supervision of the rheumatologist. This statement is 
a separate item to remind all health professionals who care for 
patients with RA that discussing with the patient the reasons for 
aiming at the selected target, the therapeutic options available 
and the strategies planned to reach the target is of utmost impor-
tance (category IV). Likewise, it is paramount that a rheuma-
tologist deﬁ  nes the target with the patient, directs the strategy 
chosen and follows the patient over time, since other professions 
are less well informed on the disease itself, the beneﬁ  ts and risks 
of individual agents to treat RA and the risks of comorbidities. In 
this regard, it may constitute a challenge to inform patients with 
early RA on the need of intensive medication or patients with 
relatively mild symptoms on the necessity to adjust therapy. 
This item therefore also implies the importance of patient edu-
cation programmes in a speciﬁ  c structured way, as well as the 
design of programmes to help health professionals address the 
appropriate issues with their patients.
Evidence and agreement
For all statements, the category of evidence and the strength 
of recommendation have been determined in accordance with 
the systematic literature review39 and are shown in table 1. In 
addition, the level of agreement as determined during the ﬁ  nal 
3–6 months) for patients in sustained low disease activity or 
remission. Progression of joint damage can be recognised within 
a few weeks in patients with high disease activity.58 Therefore, 
in patients with high disease activity, there is a need for frequent 
assessment of the disease status (eventually even monthly) to 
adapt treatment accordingly (category Ib). Once patients reach 
remission (or the alternative goal of LDA when having long-
standing RA) and sustain this state, less frequent evaluations 
may be sufﬁ  cient. The focus here is on the term ‘sustained’, indi-
cating that even if a particular desired state is reached, more fre-
quent control examinations are necessary initially to ensure that 
the state does not change (ie, rebound) rapidly. The ﬁ  rst exam-
ple for high disease activity, ‘as frequently as monthly’, leans 
against available strategic trials evaluating patients every 1–3 
months28 30 in high disease activity. The other example, ‘such as 
every 3–6 months’ has been a compromise constituting expert 
opinion, since some rheumatologists feared short-term reactiva-
tion of RA which could be detected early with 3-monthly exam-
inations. Among patients who are in sustained remission and 
are adequately informed to see their rheumatologist earlier upon 
status changes, annual control examinations may sufﬁ  ce.
(6) The use of validated composite measures of disease 
activity, which include joint assessments, is needed in routine 
clinical practice to guide treatment decisions. The Committee 
was convinced that using composite measures of disease 
activity constitutes the best way to judge disease activity and 
response to therapy, although this is an expert opinion (cate-
gory IV). RA is heterogeneous and composite scores capture this 
heterogeneity best.59 60 There exist several validated composite 
measures of disease activity which comprise joint assessment.61 
Importantly, the vast majority of the experts felt that these mea-
sures should include joint assessments, because the joints consti-
tute the ‘organ’ involved in RA and using measures that do not 
contain joint counts may lack face validity or not be accurate 
(inﬂ  uenced by factors not related to the disease). Indeed, this 
item as it stands achieved one of the highest levels of agreement 
(9.0). Recent EULAR/ACR guidelines for clinical trial reporting 
mention validated composite measures that include joint counts 
obtained by a rheumatologist or other health professional, such 
as the disease activity score (DAS) or the DAS employing 28 
joint counts (DAS28), the simpliﬁ   ed and the clinical disease 
activity index (SDAI, CDAI)50 51; these measures are also useful 
in clinical practice. To leave the choice open for the clinician, the 
neutral term ‘composite measure of disease activity’ was used.
(7) Structural changes and functional impairment should 
be considered when making clinical decisions, in addition to 
assessing composite measures of disease activity. This item 
reiterates the importance of using composite measures of dis-
ease activity, but indicates that other aspects such as functional 
impairment and joint damage, which are governed by the degree 
of disease activity, also have to be considered. However, in the 
shorter term, the majority of patients even with high disease 
activity will not experience progression of joint destruction.62 
Thus, the effect of active disease on radiographic damage var-
ies between patients. The committee felt that x-rays should be 
obtained annually and potential progression of joint damage 
be estimated (not scored). If joint damage appears to progress 
despite achieving the desired target such as LDA, intensifying 
treatment may be needed (category IV). However, lag periods 
of x-ray progression may have to be considered.63 This bullet 
point does not mention x-rays, indicating that other instru-
ments known (validated) to inform us on joint damage may 
also be used; this relates particularly to MRI and sonography. 
Importantly, judgements should be made by those sufﬁ  ciently 
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The overall targeted therapeutic approach is summarised in a 
simpliﬁ  ed form in ﬁ  gure 1.
While several items provide additional guidance in relation 
to the major statements (1) and (3), three additional recom-
mendations stick out in the context of current practice, namely 
numbers (4), (5) and (6). Recommendation (6) received one of 
the highest votes and levels of agreement and calls for the need 
to use composite disease activity measures which include joint 
counts in the follow-up of patients with RA. Indeed, 93.4% of 
the experts voted to include joint assessments. Items (4) and (5) 
recommend adjustment of therapy at least every 3 months if 
the therapeutic target is not reached and to assess patients with 
higher disease activity states within a shorter term and thus up 
to monthly to allow timely adaptation of therapy.
These recommendations come at a time when both remis-
sion and LDA are achievable goals with the current therapeu-
tic armamentarium.31 32 The recommendations are primarily 
meant to provide guidance on ways towards this goal, as seen 
by experts. They are aimed at all stakeholders: patients who 
are informed by these statements on the optimal strategies to 
prevent or contain damage and disability; rheumatologists and 
other health professionals who may further their drive to do the 
best for the patients; and also ofﬁ  cial bodies such as govern-
ments or payers which may wish to use this document as a ref-
erence for the assessment of success in treating patients with RA 
in their environment.
Many sets of recommendations have been developed in the 
past for treating early and established RA.66–68 However, none 
of these comprised the important aspects of speciﬁ  cally deﬁ  ning 
the treatment target for RA and detailing the ways to achieve 
the therapeutic goal. This is now provided with the present set 
of recommendations. Bringing them into practice will enable the 
prevention of progression of joint damage and reversal of physi-
cal disability, a pivotal goal for the new decade.
Recommendations such as those presented here usually elicit 
a number of research questions. This research agenda is implic-
itly indicated by the contents of all statements with category 
IV evidence; it would be important to perform studies which 
examine the evidence for these expert opinions. On the other 
hand, many of these category IV recommendations are based 
on a large array of indirect evidence so it would also be worth-
while to look into the possibility of improving the appraisal of 
ballot at the Expert Committee meeting is provided (table 1). 
For reasons of transparency, we also show the number of ballots 
needed for the ﬁ  nal formulation of the statements as well as the 
percentage of participants who voted for that formulation. The 
level of agreement ranged from 7.8 to 9.7 on a 10-point scale.
DISCUSSION
The recommendations presented are based on a combination of 
a systematic literature review and expert opinion.
The process was initiated by a Steering Committee which 
adhered to the EULAR operating procedures for the develop-
ment of recommendations.40 It was ﬁ  nalised after discussions 
by more than 60 experts from all over the world. Importantly, 
ﬁ  ve patients were among these experts. The very high level of 
agreement on most of the statements is also noteworthy and, 
given that the Expert Group came from so many countries and 
regions of the world, this agreement implies a broad interna-
tional recognition and consensus.
The recommendations were formulated with the optimal out-
come of RA in practice in mind. They do not account for poten-
tial ﬁ  nancial constraints or access to particular therapies, since 
no one particular type of therapy was the focus of attention but 
rather the therapeutic target that needs to be attained, indepen-
dent of accessibility. However, with different accessibilities, dif-
ferent proportions of patients may be able to attain the desired 
target, although it has been shown that adhering to treatment 
strategies may signiﬁ  cantly improve outcomes even when easily 
accessible and affordable therapies are employed.28–30
As its major conclusion, the Expert Committee was almost 
unanimous that remission must be the ultimate therapeutic 
goal in RA. However, since no therapeutic trial has studied 
this approach—for instance, by comparing it with the aim of 
achieving LDA—this recommendation is actually expert-based 
although it is supported by a large body of circumstantial evi-
dence. True evidence exists for the beneﬁ  cial effect of treating 
RA to a target of LDA in a structured strategic way when com-
pared with non-structured therapy.28 29 However, the Expert 
Committee felt that, while being an important step and a major 
alternative goal, reaching LDA could only pertain to patients 
with long-standing RA whose disease may have become refrac-
tory to therapeutic intervention. In contrast, in early RA, LDA 
should only be an intermediate step on the way to remission. 
Figure 1  Algorithm for treating rheumatoid arthritis (RA) to target based on the recommendations provided in box 1 and discussed in more detail 
in the explanatory notes. Indicated as separate threads are the main target (remission and sustained remission) and the alternative target (low 
disease activity in patients with long-term disease), but the approaches to attain the targets and sustain them are essentially identical. Adaptation of 
therapy should usually be done by performing control examinations with appropriate frequency and using composite disease activity measures which 
comprise joint counts.
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